As EBI2 expression and oxysterol dysregulation have been linked with the pathogenesis of MS (69), and as MS is characterized by a relapsing and remitting course, in which subtypes exist and in which EBI2 is variably upregulated in some of these, it is logical to suggest that heterogeneous EBI2 expression may similarly play a role in the neurological abnormalities found in CFS/ME. Here, GPR183 is linked to myeloid sarcoma.